Efficacy and tolerability of metronomic chemotherapy in patients with metastatic breast cancer – an international experience in West Sweden and in the South of Ireland.

Bray, 2020, Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin Hennigs, 2016, Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study, BMC Canc, 16, 734, 10.1186/s12885-016-2766-3 Hanahan, 2000, Less is more,regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J Clin Invest, 105, 1405, 10.1172/JCI9872 Kerbel, 2004, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer, 4, 423, 10.1038/nrc1369 Colleoni, 2002, Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels, Ann Oncol, 13, 73, 10.1093/annonc/mdf013 Dellapasqua, 2008, Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer, J Clin Oncol, 26, 4899, 10.1200/JCO.2008.17.4789 Stockler, 2011, Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer, J Clin Oncol, 29, 4498, 10.1200/JCO.2010.33.9101 Cardoso, 2020, 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†, Ann Oncol, 10.1016/j.annonc.2020.09.010 André, 2013, Has the time come for metronomics in low- income and middle-income countries?, The Lancet Oncology, 14, e239, 10.1016/S1470-2045(13)70056-1 Olin, 2000, New strategies for managing metastatic breast cancer, Oncology (Williston Park), 14, 629 Zelek, 2001, Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, Cancer, 92, 2267, 10.1002/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q Kaufman, 2015, Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, 33, 594, 10.1200/JCO.2013.52.4892 Turner, 2018, Overall survival with palbociclib and fulvestrant in advanced breast cancer, N Engl J Med, 379, 1926, 10.1056/NEJMoa1810527 Glode, 2017, Rising cost of cancer pharmaceuticals: cost Issues and Interventions to Control Costs, Pharmacotherapy, 37, 85, 10.1002/phar.1867 Calleri, 2009, Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab, Clin. Cancer Res., 15, 7652, 10.1158/1078-0432.CCR-09-1493 Browder, 2000, Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer, Cancer Res, 60, 1878 Wu, 2014, Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model, Cancer Lett, 353, 272, 10.1016/j.canlet.2014.07.033 Ge, 2012, Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome, Cancer Immunol Immunother, 61, 353, 10.1007/s00262-011-1106-3 Zelek, 2001, Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, Cancer, 92, 2267, 10.1002/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q Wildiers, 2018, Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group, Lancet Oncol, 19, 323, 10.1016/S1470-2045(18)30083-4 Vineis, 2014, Global cancer patterns: causes and prevention, Lancet, 383, 549, 10.1016/S0140-6736(13)62224-2 hse.ie. 2016. Capecitabine* reference prices. [ONLINE] Available at: https://www.hse.ie/eng/health/hl/generics/ref/capecitabine.html. [Accessed 3 August 2020]. Scoggins, 2010, A National Cancer Clinical Trials System for the 21st Century: reinvigorating the NCI Cooperative Group Program, J Natl Cancer Inst, 102, 1371, 10.1093/jnci/djq291 Martin, 2020, Cancer Res, 80, 10.1158/1538-7445.PRCA2012-C59